Altimmune, Inc. (ALT)

NASDAQ: ALT · IEX Real-Time Price · USD
12.77
+0.15 (1.19%)
At close: Sep 30, 2022 4:00 PM
12.72
-0.05 (-0.39%)
After-hours: Sep 30, 2022 7:36 PM EDT
1.19%
Market Cap 626.05M
Revenue (ttm) 3.48M
Net Income (ttm) -96.94M
Shares Out 49.03M
EPS (ttm) -2.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,266,535
Open 12.64
Previous Close 12.62
Day's Range 12.58 - 13.41
52-Week Range 3.83 - 23.49
Beta 0.18
Analysts Buy
Price Target 29.43 (+130.5%)
Earnings Date Nov 7, 2022

About ALT

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known... [Read more...]

Industry Biotechnology
CEO Vipin Garg
Employees 47
Stock Exchange NASDAQ
Ticker Symbol ALT
Full Company Profile

Financial Performance

In 2021, Altimmune's revenue was $4.41 million, a decrease of -46.12% compared to the previous year's $8.19 million. Losses were -$97.09 million, 98.0% more than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for ALT stock is "Buy." The 12-month stock price forecast is 29.43, which is an increase of 130.46% from the latest price.

Price Target
$29.43
(130.46% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Altimmune Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or...

Twenty-four week interim analysis on approximately 160 subjects planned for Q1 2023 Twenty-four week interim analysis on approximately 160 subjects planned for Q1 2023

3 days ago - GlobeNewsWire

Altimmune's (ALT) Data From NASH Study Fail to Impress Investors

Altimmune (ALT) reports positive top-line results from its 12-week phase I study evaluating pemvidutide in patients with non-alcoholic fatty liver disease. The results fail to impress investors.

2 weeks ago - Zacks Investment Research

Altimune (ALT) Stock Plummets 33% Despite Positive Clinical Data

Source: Shutterstock Altimune (NASDAQ: ALT ) stock is falling hard on Wednesday even after reporting positive results from a Phase 1b clinical trial this morning. That clinical trial concerns the use of...

2 weeks ago - InvestorPlace

Altimmune's stock falls 44% after sharing data from trial for liver disease treatment

Shares of Altimmune Inc. ALT, -0.39% tumbled 44.4% in premarket trading on Wednesday after the company shared new data from an early-stage clinical trial for its experimental treatment for non-alcoholic...

2 weeks ago - Market Watch

Altimmune Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of...

GAITHERSBURG, Md., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced positive topline results from its 12-week Phase 1b study ...

2 weeks ago - GlobeNewsWire

Altimmune, Inc. (ALT) Reports Q2 Loss, Misses Revenue Estimates

Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 6.67% and 99.54%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

7 Biotech Stocks to Buy for Q3

These biotech stocks could be good buys due for a few reasons, including great R&D pipelines and treatments with promising market potential. The post 7 Biotech Stocks to Buy for Q3 appeared first on Inv...

2 months ago - InvestorPlace

Here's Why Altimmune, Inc. (ALT) is a Great Momentum Stock to Buy

Does Altimmune, Inc. (ALT) have what it takes to be a top stock pick for momentum investors? Let's find out.

2 months ago - Zacks Investment Research

Is Altimmune (ALT) Stock Outpacing Its Medical Peers This Year?

Here is how Altimmune, Inc. (ALT) and argenex (ARGX) have performed compared to their sector so far this year.

2 months ago - Zacks Investment Research

Is Altimmune (ALT) Outperforming Other Medical Stocks This Year?

Here is how Altimmune, Inc. (ALT) and Chinook Therapeutics (KDNY) have performed compared to their sector so far this year.

3 months ago - Zacks Investment Research

Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming EASL International Liver Congress™ on ...

Presentation to be highlighted in the Best of International Liver Congress Presentation to be highlighted in the Best of International Liver Congress

3 months ago - GlobeNewsWire

Has Altimmune (ALT) Outpaced Other Medical Stocks This Year?

Here is how Altimmune, Inc. (ALT) and Sensus Healthcare, Inc. (SRTS) have performed compared to their sector so far this year.

3 months ago - Zacks Investment Research

Wall Street Analysts Think Altimmune, Inc. (ALT) Could Surge 352%: Read This Before Placing a Bet

The mean of analysts' price targets for Altimmune, Inc. (ALT) points to a 352.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among an...

3 months ago - Zacks Investment Research

Altimmune to Participate at Two Upcoming Investor Conferences

GAITHERSBURG, Md., June 03, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will partici...

3 months ago - GlobeNewsWire

Altimmune to Present Pemvidutide Clinical Data at Upcoming American Diabetes Association Scientific Sessions June 6, ...

GAITHERSBURG, Md., May 31, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Samuel Klein, William H. Danforth Professor of Med...

4 months ago - GlobeNewsWire

Wall Street Analysts See a 426% Upside in Altimmune, Inc. (ALT): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 425.9% in Altimmune, Inc. (ALT). While the effectiveness of this highly sought-after metric is questionable, the ...

4 months ago - Zacks Investment Research

Altimmune to Present Pemvidutide Clinical Data at Upcoming Global NASH Congress May 27, 2022

GAITHERSBURG, Md., May 20, 2022 (GLOBE NEWSWIRE) --  Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune,...

4 months ago - GlobeNewsWire

Altimmune to Present at Upcoming Investor Conferences

GAITHERSBURG, Md., May 16, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company's management team will particip...

4 months ago - GlobeNewsWire

Altimmune, Inc. (ALT) Reports Q1 Loss, Misses Revenue Estimates

Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 22.81% and 98.45%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Altimmune Announces Initiation of 48-week Phase 2 MOMENTUM Trial of Pemvidutide in Obesity

The Company also announces completion of enrollment in 12-week, Phase 1b trial of pemvidutide in subjects with non-alcoholic fatty liver disease (NAFLD) The Company also announces completion of enrollme...

6 months ago - GlobeNewsWire

Altimmune, Inc. (ALT) Reports Q4 Loss, Tops Revenue Estimates

Altimmune, Inc. (ALT) delivered earnings and revenue surprises of 23.44% and 2,145.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update

Data readouts from multiple clinical trials expected during the next 6 to 12 months

6 months ago - GlobeNewsWire

Altimmune to Report Fourth Quarter and Full Year 2021 Financial Results on March 15, 2022

GAITHERSBURG, Md., March 08, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2021...

6 months ago - GlobeNewsWire

Analysts Estimate Altimmune, Inc. (ALT) to Report a Decline in Earnings: What to Look Out for

Altimmune, Inc. (ALT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

Altimmune's Mid-Stage Pemvidutide Study Cleared By FDA For Obesity

The FDA has cleared Altimmune Inc's ALT Investigational New Drug (IND) application for its Phase 2 trial of pemvidutide for obesity.  [ALERT] Nic Chahine shares his Bear Market Beating options trading s...

8 months ago - Benzinga